Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'PharmaVitae : Merck and Co.' returned 25 results - Page 1 of 2   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Merck & Co., Inc.: PharmaVitae Profile   Datamonitor, Nov 2010, Pages: 117 , 2003–15 Financial performance, 2003–15 Merck & Co.: PharmaVitae forecasts at a glance Strategic insight SWOT analysis Chapter 3 Quarterly news update Latest quarterly sales Latest quarterly Merck & Co. Inc: PharmaVitae Profile   Datamonitor, June 2010, Pages: 107 with Schering-Plough -Analyze the impact of generic erosion across key Merck & Co. brands over 09-15 and how this threat will mitigate sales growth from new launches Chapter 1 About this profile PharmaVitae Merck & Co. Inc: PharmaVitae Model   Datamonitor, Jan 2009 and pipeline data Merck & Co. Inc: PharmaVitae Model Les Laboratoires Servier: PharmaVitae Profile   Datamonitor, Nov 2010, Pages: 76 one product, Coversyl Executive Summary Key findings Prescription pharmaceutical sales and growth rate performance, 2003– Servier: PharmaVitae forecasts at a glance Strategic insight Boehringer Ingelheim GmbH: PharmaVitae Profile   Datamonitor, Dec 2010, Pages: 73 SmithKline Plc IMS Health Johnson & Johnson Merck & Co., Inc. Novartis AG Pfizer Inc Boehringer Ingelheim GmbH: PharmaVitae Profile Allergan Inc.: PharmaVitae Profile   Datamonitor, Nov 2010, Pages: 89 Executive Summary Key findings Prescription pharmaceutical sales and growth rate performance, 2003– Financial performance, 2003– Allergan: PharmaVitae forecasts at a glance Strategic insight Daiichi Sankyo Co., Ltd: PharmaVitae Profile   Datamonitor, Dec 2010, Pages: 59 Pfizer Inc Santen Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd: PharmaVitae Profile Shire plc: PharmaVitae Profile   Datamonitor, Dec 2010, Pages: 62 Prescription pharmaceutical sales and growth rate performance, 2003– Financial performance, 2003– Shire: PharmaVitae forecasts at a glance Strategic insight Shire’s ADHD franchise growth Menarini: PharmaVitae Profile   Datamonitor, June 2010, Pages: 48 Nordisk A/S Pfizer Inc Servier Taisho Pharmaceutical Co., Ltd. Menarini: PharmaVitae Profile Sanofi-Aventis: PharmaVitae Profile   Datamonitor, Nov 2010, Pages: 135 . Executive Summary Key findings Prescription pharmaceutical sales and growth rate performance, 2003– Financial performance, 2003– Sanofi-Aventis: PharmaVitae forecasts at a glance Strategic Pfizer Inc.: PharmaVitae Profile   Datamonitor, Nov 2010, Pages: 122 -2011 Executive Summary Key findings Prescription pharmaceutical sales and growth rate performance, 2003– Financial performance, 2003– Pfizer: PharmaVitae forecasts at a glance Strategic Abbott Laboratories: PharmaVitae Profile   Datamonitor, May 2011, Pages: 95 Company, The Merck & Co., Inc. Merck KGaA Novartis AG Pfizer Inc Schering-Plough Corporation Solvay Group The Depository Trust & Clearing Corporation Wyeth Abbott Laboratories: PharmaVitae Profile Eli Lilly & Co.: PharmaVitae Profile   Datamonitor, July 2010, Pages: 101 & Johnson Merck & Co., Inc. NICE Systems Ltd Novartis AG Novo Nordisk A/S Pfizer Inc Pivotal Corporation Eli Lilly & Co.: PharmaVitae Profile Takeda Pharmaceutical Co., Ltd: PharmaVitae Profile   Datamonitor, Oct 2010, Pages: 98 Pharmaceutical Products, Inc. The Depository Trust & Clearing Corporation Wyeth Takeda Pharmaceutical Co., Ltd: PharmaVitae Profile Key Companies: Osteoporosis - Growing competition threatens leading franchises and drives innovation   Datamonitor, Nov 2011, Pages: 34 - In-depth discussion of brand lifecycle and portfolio management strategies of key companies involved in the osteoporosis market. - Review Merck & Co.'s and Servier’s osteoporosis portfolio management Bristol-Myers Squibb Co.: PharmaVitae Profile   Datamonitor, March 2011, Pages: 84 an imminent wave of generic compeitition. - Assess what makes BMS a model biopharma company and why its newfound focus could lead to the industry's next megamerger ABOUT THIS PROFILE - PharmaVitae Explorer Astellas Pharma Inc.: PharmaVitae Profile   Datamonitor, Oct 2010, Pages: 95 Shionogi & Co., Ltd. The Depository Trust & Clearing Corporation Toyama Chemical Co. Ltd XenoPort, Inc Astellas Pharma Inc.: PharmaVitae Profile Product Profiles: Marketed Antibacterials - Increasing genericization and fragmentation shape a crowded market   Datamonitor, Nov 2011, Pages: 110 positioning Clinical and commercial attractiveness Avelox/Octegra (moxifloxacin; Bayer/Merck & Co.) Drug profile Development overview SWOT analysis Product positioning Bayer Schering Pharma AG: PharmaVitae Profile   Datamonitor, June 2010, Pages: 116 enhanced the company's HealthCare division -Assess how an increased healthcare focus and merger-related synergies will drive an increase in operating profit Chapter 1 About this profile PharmaVitae Gilead Sciences Inc.: PharmaVitae Profile   Datamonitor, Sep 2009, Pages: 88 . Merck & Co., Inc. NASDAQ Stock Market, Inc. Novartis AG Pfizer Inc Gilead Sciences Inc.: PharmaVitae Profile Results:  First -   Prev -   1 -   2 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network